Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TSSK1B | Q9BXA7 | 1/20 | 0.32 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27643168 | 0.81 | LMNA (0.34) | CES2CES1LMNAGSK3BTDP1 | |
| SCHEMBL564105 | 0.78 | GSK3B (0.56) | CES2CES1LMNAGSK3BTDP1 | |
| SCHEMBL27994581 | 0.78 | PDPK1 (0.52) | CES2CES1LMNAGSK3BTDP1 | |
| SCHEMBL4316411 | 0.78 | KDM4E (0.47) | CES2CES1LMNAGSK3BTDP1 | |
| Water SCHEMBL468373 | 0.77 | CES1 (0.60) | CES2CES1LMNATDP1L3MBTL1 | |
| SCHEMBL17201709 | 0.76 | SPHK1 (0.32) | CES2CES1LMNAL3MBTL1 | |
| Water SCHEMBL836625 | 0.75 | TSHR (0.60) | CES2CES1 | |
| SCHEMBL28131090 | 0.75 | KMT2A (0.36) | LMNAGSK3BTDP1L3MBTL1 | |
| SCHEMBL27338904 | 0.75 | ELANE (0.33) | LMNAGSK3BTDP1L3MBTL1 | |
| SCHEMBL27262005 | 0.75 | ELANE (0.33) | LMNAGSK3BTDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071776-B2 | Nanoparticles for treatment of allergy | N-FOLD LLC (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200246445-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | ALLERTEIN THERAPEUTICS, LLC | 2020-08-06 | — | — | US | disclosed |
| US-9919058-B2 | Polyketal particles including a CpG oligodeoxynucleotide for the treatment of lung cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170224801-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | ALLERTEIN THERAPEUTICS, LLC (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170202977-A1 | POLYKETAL PARTICLES INCLUDING A CPG OLIGODEOXYNUCLEOTIDE FOR THE TREATMENT OF LUNG CANCER | The United States of America, as represented by the Secretary, Department of Health and | 2017-07-20 | — | — | US | disclosed |
| US-9597385-B2 | Nanoparticles for treatment of allergy | ALLERTEIN THERAPEUTICS, LLC (US) | 2017-03-21 | — | — | US | disclosed |
| WO-2016010788-A1 | POLYKETAL PARTICLES INCLUDING A CPG OLIGODEOXYNUCLEOTIDE FOR THE TREATMENT OF LUNG CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2016-01-21 | — | — | WO | disclosed |
| US-20150174225-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | N-FOLD LLC | 2015-06-25 | — | — | US | disclosed |
| EP-2841098-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | Allertein Therapeutics, LLC (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2013163176-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | ALLERTEIN THERAPEUTICS, LLC (US) | 2013-10-31 | — | — | WO | disclosed |
| US-8252846-B2 | Strategies for delivery of active agents using micelles and particles | EMORY UNIVERSITY (US) | 2012-08-28 | — | — | US | disclosed |
| EP-1893661-B1 | STRATEGIES FOR DELIVERY OF ACTIVE AGENTS USING MICELLES AND PARTICLES | UNIV EMORY (US) | 2012-01-18 | — | — | EP | disclosed |
| US-20100062968-A1 | Novel strategies for delivery of active agents using micelles and particles | NATIONAL INSTITUTES OF HEALTH-DIRECTOR DEITR | 2010-03-11 | — | — | US | disclosed |
| EP-2146747-A1 | NOVEL STRATEGIES FOR DELIVERY OF ACTIVE AGENTS USING MICELLES AND PARTICLES | Emory University (US) | 2010-01-27 | — | — | EP | disclosed |
| US-20090011993-A1 | Novel strategies for delivery of active agents using micelles and particles | GEORGIA TECH RESEARCH CORPORATION | 2009-01-08 | — | — | US | disclosed |
| WO-2008127532-A1 | NOVEL STRATEGIES FOR DELIVERY OF ACTIVE AGENTS USING MICELLES AND PARTICLES | EMORY UNIVERSITY (US) | 2008-10-23 | — | — | WO | disclosed |
| EP-1893661-A2 | STRATEGIES FOR DELIVERY OF ACTIVE AGENTS USING MICELLES AND PARTICLES | EMORY UNIVERSITY (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006122223-A2 | STRATEGIES FOR DELIVERY OF ACTIVE AGENTS USING MICELLES AND PARTICLES | EMORY UNIVERSITY (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174225-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | TLR3, CD47, TLR5 | CES2 2450/4885CES1 2521/4885LMNA 4192/4885 |
| US-20090011993-A1 | Novel strategies for delivery of active agents using micelles and particles | CD47, CHMP4B, MASP2 | CES2 2141/4885CES1 1065/4885LMNA 1391/4885 |
| US-20170224801-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | TLR3, CD47, TLR5 | CES2 2450/4885CES1 2521/4885LMNA 4192/4885 |
| US-11071776-B2 | Nanoparticles for treatment of allergy | TLR3, CD47, TLR5 | CES2 2450/4885CES1 2521/4885LMNA 4192/4885 |
| US-20170202977-A1 | POLYKETAL PARTICLES INCLUDING A CPG OLIGODEOXYNUCLEOTIDE FOR THE TREATMENT OF LUNG CANCER | POLK, POLQ, DCK | CES2 4297/4885CES1 4092/4885LMNA 2179/4885 |
| US-20200246445-A1 | NANOPARTICLES FOR TREATMENT OF ALLERGY | TLR3, CD47, TLR5 | CES2 2450/4885CES1 2521/4885LMNA 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.